Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | LOX | P28300 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HRH2 | P25021 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3975713 | 0.88 | KEAP1 (0.45) | ALOX15KDM1AKDM4ELOXSMN1; SMN2 | |
| SCHEMBL10262951 | 0.80 | MEN1 (0.46) | KDM1AKDM4ENPSR1SMN1; SMN2CYP2D6 | |
| SCHEMBL1098206 | 0.80 | KDM1A (0.45) | KDM1AKDM4ELOXNPSR1SMN1; SMN2 | |
| SCHEMBL1098209 | 0.78 | ALDH1A1 (0.51) | KDM1AKDM4ENPSR1SMN1; SMN2CYP2D6 | |
| SCHEMBL477191 | 0.78 | KDM1A (0.44) | KDM1AKDM4ELOXNPSR1SMN1; SMN2 | |
| SCHEMBL1359879 | 0.78 | KDM1A (0.44) | KDM1AKDM4ELOXNPSR1SMN1; SMN2 | |
| SCHEMBL23775597 | 0.78 | GAA (0.55) | ALOX15KDM4ESMN1; SMN2ALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL10711166 | 0.77 | KDM1A (0.43) | KDM1AKDM4ELOXNPSR1SMN1; SMN2 | |
| SCHEMBL1100792 | 0.77 | KDM1A (0.43) | KDM1AKDM4ELOXNPSR1SMN1; SMN2 | |
| SCHEMBL14670865 | 0.77 | PTGS2 (0.54) | KDM1AKDM4ENPSR1PTGS2HRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12440494-B2 | Compounds useful for inhibiting RAF dimers | ALBERT EINSTEIN COLLEGE OF MEDICINE (US) | 2025-10-14 | — | — | US | disclosed |
| WO-2024163380-A1 | SUBSTITUTED BENZIMIDAZOLE COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-08-08 | — | — | WO | disclosed |
| US-20240190891-A1 | PYRIDO OXAZINE AMINO DERIVATIVES AS ALK5 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-06-13 | — | — | US | disclosed |
| EP-4182323-B1 | PYRIDO OXAZINE AMINO DERIVATIVES AS ALK5 INHIBITORS | CHIESI FARM SPA (IT) | 2024-04-24 | — | — | EP | disclosed |
| EP-4182323-A1 | PYRIDO OXAZINE AMINO DERIVATIVES AS ALK5 INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2023-05-24 | — | — | EP | disclosed |
| CN-116075307-A | Pyridooxazine amino derivatives as ALK5 inhibitors | 奇斯药制品公司 | 2023-05-05 | — | — | CN | disclosed |
| US-20220265669-A1 | COMPOUNDS USEFUL FOR INHIBITING RAF DIMERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-08-25 | — | — | US | disclosed |
| US-20220265669-A1 | COMPOUNDS USEFUL FOR INHIBITING RAF DIMERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-08-25 | — | — | US | disclosed |
| US-20220259226-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2022-08-18 | — | — | US | disclosed |
| US-20220119419-A1 | BYCYCLIC JAK INHIBITORS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (HK) | 2022-04-21 | — | — | US | disclosed |
| US-10301272-B2 | Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ROR[γ] | PHENEX PHARMACEUTICALS AG (DE) | 2019-05-28 | — | — | US | disclosed |
| US-20190055264-A1 | Macrocyclic MCL-1 inhibitors and methods of use | AbbVie Deutschland GmbH & Co. KG (DE) | 2019-02-21 | — | — | US | disclosed |
| US-9815851-B2 | Pyrrolo carboxamides as modulators of orphan nuclear receptor RAR-related orphan receptor-gamma (RORγ, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseases | PHENEX PHARMACEUTICALS AG (DE) | 2017-11-14 | — | — | US | disclosed |
| EP-3118189-A1 | CARBOXAMIDE OR SULFONAMIDE SUBSTITUTED NITROGEN-CONTAINING 5-MEMBERED HETEROCYCLES AS MODULATORS FOR THE ORPHAN NUCLEAR RECEPTOR ROR GAMMA | Phenex Pharmaceuticals AG (DE) | 2017-01-18 | — | — | EP | disclosed |
| EP-2882710-B1 | CARBOXAMIDE OR SULFONAMIDE SUBSTITUTED NITROGEN-CONTAINING 5-MEMBERED HETEROCYCLES AS MODULATORS FOR THE ORPHAN NUCLEAR RECEPTOR ROR GAMMA | PHENEX PHARMACEUTICALS AG (DE) | 2016-09-07 | — | — | EP | disclosed |
| US-20150175562-A1 | CARBOXAMIDE OR SULFONAMIDE SUBSTITUTED THIAZOLES AND RELATED DERIVATIVES AS MODULATORS FOR THE ORPHAN NUCLEAR RECEPTOR ROR[GAMMA] | PHENEX PHARMACEUTICALS AG (DE) | 2015-06-25 | — | — | US | disclosed |
| US-20150175562-A1 | CARBOXAMIDE OR SULFONAMIDE SUBSTITUTED THIAZOLES AND RELATED DERIVATIVES AS MODULATORS FOR THE ORPHAN NUCLEAR RECEPTOR ROR[GAMMA] | PHENEX PHARMACEUTICALS AG (DE) | 2015-06-25 | — | — | US | disclosed |
| WO-2013079223-A1 | PYRROLO CARBOXAMIDES AS MODULATORS OF ORPHAN NUCLEAR RECEPTOR RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORϒ, NR1F3) ACTIVITY AND FOR THE TREATMENT OF CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES | PHENEX PHARMACEUTICALS AG (DE) | 2013-06-06 | — | — | WO | disclosed |
| US-20120083489-A1 | BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR ANTAGONISTS | GLAXOSMITHKLINE LLC | 2012-04-05 | — | — | US | disclosed |
| WO-2010141539-A1 | BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS | GLAXOSMITHKLINE LLC (US) | 2010-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083489-A1 | BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR ANTAGONISTS | MCHR1, MCHR2, MC1R | ALOX15 1969/4885KDM1A 1380/4885KDM4E 1578/4885 |
| US-20220265669-A1 | COMPOUNDS USEFUL FOR INHIBITING RAF DIMERS | BRAF, RAF1, NRAS | ALOX15 3581/4885KDM1A 3719/4885KDM4E 4113/4885 |
| US-20190055264-A1 | Macrocyclic MCL-1 inhibitors and methods of use | MCL1, BCL2A1, BCL2L10 | ALOX15 2524/4885KDM1A 981/4885KDM4E 1735/4885 |
| US-20220119419-A1 | BYCYCLIC JAK INHIBITORS AND USES THEREOF | JAK1, JAK2, JAK3 | ALOX15 784/4885KDM1A 601/4885KDM4E 662/4885 |
| US-12440494-B2 | Compounds useful for inhibiting RAF dimers | BRAF, RAF1, NRAS | ALOX15 3772/4885KDM1A 3882/4885KDM4E 4256/4885 |
| US-20150175562-A1 | CARBOXAMIDE OR SULFONAMIDE SUBSTITUTED THIAZOLES AND RELATED DERIVATIVES AS MODULATORS FOR THE ORPHAN NUCLEAR RECEPTOR ROR[GAMMA] | RORA, RORB, RORC | ALOX15 2797/4885KDM1A 1647/4885KDM4E 2241/4885 |
| US-20220259226-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | ALOX15 2524/4885KDM1A 981/4885KDM4E 1735/4885 |
| US-20240190891-A1 | PYRIDO OXAZINE AMINO DERIVATIVES AS ALK5 INHIBITORS | TGFBR1, ACVR1, ALK | ALOX15 442/4885KDM1A 1059/4885KDM4E 575/4885 |
| US-10301272-B2 | Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ROR[γ] | RORA, RORB, RORC | ALOX15 2605/4885KDM1A 1630/4885KDM4E 2217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.